Skip to main content
Erschienen in: Allergy, Asthma & Clinical Immunology 2/2014

Open Access 01.12.2014 | Meeting abstract

C-CARE: comparing three years of anaphylaxis in children treated at the Montreal Children’s Hospital

Erschienen in: Allergy, Asthma & Clinical Immunology | Sonderheft 2/2014

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
Sarah De Schryver and Moshe Ben-Shoshan contributed equally to this work.

Background

The Cross-Canada Anaphylaxis Registry (C-CARE) aims to examine burden, triggers, management and temporal trends in anaphylaxis.

Methods

Over a three-year period (April 2011 to April 2014), data were collected on anaphylaxis cases at the Montreal Children’s Hospital emergency department (ED). Cases were recruited either prospectively or identified retrospectively based on chart review through ICD10 codes related to anaphylaxis. Logistic regressions were conducted to determine the association between sociodemographic and clinical characteristics and development of severe reactions as well as epinephrine use.

Results

Among 624 cases the median age was 5.7 years (IQR 2.4-11.7) and the majority (56.6%) were males. The percentage of anaphylaxis among all ED visits increased from 0.22% (95% CI 0.18%, 0.24%) in 2011 to 0.3% (95% CI 0.25%, 0.33%) in 2014, yielding a difference of 0.08% (95%CI, 0.03%, 0.13%). The major trigger was food (81.4%), mainly peanut and tree-nut. Most cases were moderate (70.2%) (breathing difficulties, stridor, diarrhea, crampy abdominal pain, recurrent vomiting).
Of all reactions 28.7% were not administered epinephrine. Almost 95% were prescribed or had an epinephrine auto-injector (71.6% Epipen , 22.7% Allerject).
Factors associated with severe reactions included history of peanut allergy, asthma and steroid treatment in ED. (Table 1)
Table 1
Logistic regressions assessing severe reactions and use of epinephrine
Severe reactions
Variable
OR, 95%CI
Asthma
2.3 (1. 5)
Use of steroids in ED
2.5 (1.2, 5.2)
Peanut allergy
2.2 (1, 4.9)
No use of epinephrine
Use of steroids in ED
0.2 (0.1, 0.4)
Known food allergy
0.3 (0.2, 0.5)
Use of more than 2 epinephrine in ED
Use of epinephrine outside
0.06 (0.01, 0.6)
Use of steroids in ED
9.0 (2.6, 31)
Severe reaction
16.8 (4.7, 61)
Tree-nut allergy
5.4 (1.2, 24)
Management of anaphylaxis with at least one dose of epinephrine was associated with known food allergy and use of steroids in ED.
Administration of two or more epinephrine doses in ED was less likely in those who received epinephrine outside ED and more likely with severe reactions, reactions triggered by tree-nut and in those treated with steroids in ED.

Conclusions

The percentage of anaphylaxis cases among all ED visits increased by almost 40% over a three-year period. Prompt use of epinephrine may prevent use of subsequent multiple doses of epinephrine in ED. Reactions triggered by tree-nut are more prone to require treatment with multiple doses of epinephrine.

Acknowledgment

This project was supported by AllerGEN, Health Canada and Sanofi
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
The Creative Commons Public Domain Dedication waiver (https://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Metadaten
Titel
C-CARE: comparing three years of anaphylaxis in children treated at the Montreal Children’s Hospital
Publikationsdatum
01.12.2014
Erschienen in
Allergy, Asthma & Clinical Immunology / Ausgabe Sonderheft 2/2014
Elektronische ISSN: 1710-1492
DOI
https://doi.org/10.1186/1710-1492-10-S2-A3

Weitere Artikel der Sonderheft 2/2014

Allergy, Asthma & Clinical Immunology 2/2014 Zur Ausgabe

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.